• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Makale Koleksiyonu
  • View Item
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Advanced Search

Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis

Thumbnail

View/Open

Yayıncı Sürümü - Makale (426.2Kb)

Access

info:eu-repo/semantics/openAccess

Date

2015

Author

Başer, Onur
Ganguli, Arijit
Roy, Sanjoy
Xie, Lin
Cifaldi, Mary

Metadata

Show full item record

Citation

Baser, O., Ganguli, A., Roy, S., Xie, L., & Cifaldi, M. (July 01, 2015). Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis. Clinical Therapeutics, 37, 7, 1454-1465.

Abstract

Purpose: Despite improved clinical outcomes for the majority of patients, nearly 30% of patients with rheumatoid arthritis (RA) who initiate tumor necrosis factor antagonist (anti-TNF) biologic agents fail to respond to their first-line anti-TNF and switch to another anti-TNF or a non-TNF biologic. How this change affects health care costs and resource utilization is unknown. We therefore compared RA patients taking first-line anti-TNFs who switched to a second anti-TNF versus those patients who switched to an alternate biologic. Methods: Health care claims data were obtained from a large US database for eligible adults with confirmed RA diagnoses who initiated anti-TNF treatment and switched to another biologic. Health care costs and utilization during the first 12 months' postswitch were compared. Generalized linear models were used to adjust for differences in demographic and clinical characteristics before switching. Findings: Patients who switched to a second anti-TNF rather than a non-TNF biologic were generally younger (53.0 vs. 55.3 years; P < 0.0001) and less likely to be female (79.7% vs. 82.7%; P = 0.0490). Of the 3497 eligible patients who switched from first-line anti-TNFs, 2563 (73.3%) switched to another anti-TNF and 934 (26.7%) switched to a non-TNF. Adalimumab was the most frequently prescribed (43.4%) second-line anti-TNF, and abatacept was the most common non anti-TNF (71.4%). Patients who switched to a second anti-TNF remained on their first medication for a significantly shorter period (342.5 vs 420.6 days; P < 0.0001) and had lower comorbidity indices and higher disease severity at baseline than those who switched to a non anti-TNF. After adjusting for baseline differences, patients who switched to second anti-TNFs versus a non-TNF incurred lower RA-related costs ($20,938.9 vs $22,645.2; P = 0.0010) and total health care costs ($34,894.6 vs $38,437.2; P = 0.0010) 1 year postswitch. These differences were driven by increased physician office visit costs among the non-TNF group. Implications: Among the anti-TNF initiators who switched therapy, more patients switched to a second anti-TNF than to a non-TNF. Switching to a second anti-TNF treatment was associated with lower all-cause and RA-related health care costs and resource utilization than switching to a non-TNF. Because switching therapy may be unavoidable, finding a treatment algorithm mitigating this increase to any extent should be considered. These data are limited by their retrospective design. Additional confounding variables that could not be controlled for may affect results. (C) 2015 The Authors. Published by Elsevier HS journals, Inc.

Source

Clinical Therapeutics

Volume

37

Issue

7

URI

http://dx.doi.org/10.1016/j.clinthera.2015.04.012
https://hdl.handle.net/20.500.11779/644

Collections

  • Araştırma Çıktıları, PubMed Koleksiyonu [70]
  • Araştırma Çıktıları, Scopus İndeksli Yayınlar Koleksiyonu [429]
  • Araştırma Çıktıları, WOS İndeksli Yayınlar Koleksiyonu [470]
  • İİSBF, EB, Makale Koleksiyonu [61]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@MEF

by OpenAIRE

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || MEF University || OAI-PMH ||

MEF University Library, İstanbul, Turkey
If you find any errors in content please report us

Creative Commons License
MEF University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@MEF:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.